IGC Pharma Inc (AMEX: IGC) on Tuesday, soared 4.87% from the previous trading day, before settling in for the closing price of $0.30. Within the past 52 weeks, IGC’s price has moved between $0.25 and $0.55.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -23.45%. The company achieved an average annual earnings per share of 54.55%. With a float of $54.38 million, this company’s outstanding shares have now reached $78.20 million.
Let’s determine the extent of company efficiency that accounts for 67 employees. In terms of profitability, gross margin is 51.46%, operating margin of -663.75%, and the pretax margin is -712.7%.
IGC Pharma Inc (IGC) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of IGC Pharma Inc is 31.76%, while institutional ownership is 3.59%. The most recent insider transaction that took place on Sep 25 ’24, was worth 200,000. In this transaction Director of this company bought 588,235 shares at a rate of $0.34, taking the stock ownership to the 942,402 shares. Before that another transaction happened on Aug 12 ’24, when Company’s Director proposed sale 200,000 for $0.39, making the entire transaction worth $78,200.
IGC Pharma Inc (IGC) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 54.55% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 18.29% during the next five years compared to -13.79% drop over the previous five years of trading.
IGC Pharma Inc (AMEX: IGC) Trading Performance Indicators
IGC Pharma Inc (IGC) is currently performing well based on its current performance indicators. A quick ratio of 0.59 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 20.08.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.12, a number that is poised to hit -0.02 in the next quarter and is forecasted to reach -0.10 in one year’s time.
Technical Analysis of IGC Pharma Inc (IGC)
Looking closely at IGC Pharma Inc (AMEX: IGC), its last 5-days average volume was 0.23 million, which is a drop from its year-to-date volume of 0.32 million. As of the previous 9 days, the stock’s Stochastic %D was 38.21%. Additionally, its Average True Range was 0.02.
During the past 100 days, IGC Pharma Inc’s (IGC) raw stochastic average was set at 51.06%, which indicates a significant increase from 36.87% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 48.97% in the past 14 days, which was higher than the 48.90% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.2986, while its 200-day Moving Average is $0.3387. However, in the short run, IGC Pharma Inc’s stock first resistance to watch stands at $0.3215. Second resistance stands at $0.3306. The third major resistance level sits at $0.3351. If the price goes on to break the first support level at $0.3079, it is likely to go to the next support level at $0.3034. Should the price break the second support level, the third support level stands at $0.2943.
IGC Pharma Inc (AMEX: IGC) Key Stats
Market capitalization of the company is 24.90 million based on 79,685K outstanding shares. Right now, sales total 1,350 K and income totals -13,000 K. The company made 260 K in profit during its latest quarter, and -1,830 K in sales during its previous quarter.
